Live Breaking News & Updates on Aeglea biotherapeutics company profile

Aeglea BioTherapeutics (NASDAQ:AGLE) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Free Report) in a report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Aeglea BioTherapeutics Stock Performance The stock has a market cap of $48.64 million, a PE ratio of -0.16 and a beta of 2.57. The company […]

Aeglea-biotherapeutics , Vr-adviser , Driehaus-capital-management , Goldman-sachs-group-inc , Affinity-asset-advisors , Aeglea-biotherapeutics-company-profile , Aeglea-biotherapeutics-inc , Free-report , Asset-advisors , Capital-management , Goldman-sachs-group , Get-free-report

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives $20.00 Consensus PT from Analysts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Receives $20.00 Consensus PT from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Aeglea-biotherapeutics , Goldman-sachs-group-inc , Nasdaq , Aeglea-biotherapeutics-company-profile , Aeglea-biotherapeutics-inc , Millennium-management , Charles-schwab-investment-management-inc , Acadian-asset-management , Get-free-report , Schwab-investment-management , Asset-management , Street-corp

Aeglea BioTherapeutics (NASDAQ:AGLE) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Free Report) in a research note released on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, Wells Fargo & Company increased their target price on shares of Aeglea BioTherapeutics from $8.75 to $12.50 and gave the stock an equal weight […]

Aeglea-biotherapeutics , Goldman-sachs-group-inc , Wells-fargo-company , Aeglea-biotherapeutics-company-profile , Sphera-funds-management , Aeglea-biotherapeutics-inc , Charles-schwab-investment-management-inc , Free-report , Wells-fargo , Sachs-group , Schwab-investment-management , Sigma-advisers

Analysts Set Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) PT at $20.00

Analysts Set Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) PT at $20.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Aeglea-biotherapeutics , Sphera-funds-management , Renaissance-technologies , Aeglea-biotherapeutics-inc , Charles-schwab-investment-management-inc , Aeglea-biotherapeutics-company-profile , Wells-fargo-company , Nasdaq , Get-free-report , Marketbeat-ratings , Schwab-investment-management , Sigma-advisers

Aeglea BioTherapeutics (NASDAQ:AGLE) Stock Price Crosses Below 50-Day Moving Average of $11.42

Aeglea BioTherapeutics (NASDAQ:AGLE) Stock Price Crosses Below 50-Day Moving Average of $11.42
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Aeglea-biotherapeutics , Charles-schwab-investment-management-inc , Acadian-asset-management , Aeglea-biotherapeutics-company-profile , Wells-fargo-company , Carlyle-group-inc , Walleye-capital , Aeglea-biotherapeutics-inc , Nasdaq , Get-free-report , Point-capital-management , Schwab-investment-management

Aeglea BioTherapeutics (AGLE) Set to Announce Quarterly Earnings on Wednesday

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Free Report) is scheduled to issue its quarterly earnings data on Wednesday, November 1st. Aeglea BioTherapeutics (NASDAQ:AGLE – Get Free Report) last posted its earnings results on Friday, August 11th. The biotechnology company reported ($41.50) EPS for the quarter, missing analysts’ consensus estimates of ($4.50) by ($37.00). The company had […]

Stifel-nicolaus , Aeglea-biotherapeutics , Wells-fargo-company , Aeglea-biotherapeutics-company-profile , Goldman-sachs-group-inc , Sphera-funds-management , Renaissance-technologies , Aeglea-biotherapeutics-inc , Millennium-management , Get-free-report , Sachs-group

Aeglea BioTherapeutics (NASDAQ:AGLE) Downgraded by StockNews.com to "Sell"

StockNews.com cut shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Free Report) from a hold rating to a sell rating in a research report released on Tuesday morning. Several other research analysts have also weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Aeglea BioTherapeutics in a report on Tuesday, July 25th. They set […]

Stifel-nicolaus , Aeglea-biotherapeutics , Driehaus-capital-management , Vr-adviser , Nasdaq , Aeglea-biotherapeutics-inc , Aeglea-biotherapeutics-company-profile , Goldman-sachs-group-inc , Affinity-asset-advisors , Wells-fargo-company , Free-report

Aeglea BioTherapeutics (NASDAQ:AGLE) Upgraded to Hold at StockNews.com

Aeglea BioTherapeutics (NASDAQ:AGLE) Upgraded to Hold at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel-nicolaus , Aeglea-biotherapeutics , Affinity-asset-advisors , Aeglea-biotherapeutics-company-profile , Wells-fargo-company , Aeglea-biotherapeutics-inc , Driehaus-capital-management , Millennium-management , Vr-adviser , Get-free-report , Asset-advisors

Brokerages Set Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Price Target at $1.88

Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Free Report) have received an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month […]

Aeglea-biotherapeutics , Stifel-nicolaus , Wells-fargo-company , Acadian-asset-management , Nasdaq , Charles-schwab-investment-management-inc , Aeglea-biotherapeutics-inc , Nantahala-capital-management , Aeglea-biotherapeutics-company-profile , Get-free-report , Marketbeat-ratings , Asset-management

Aeglea BioTherapeutics (NASDAQ:AGLE) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Free Report) from a hold rating to a sell rating in a research report report published on Sunday morning. Several other equities research analysts have also recently weighed in on the company. Jonestrading reiterated a hold rating on shares of Aeglea BioTherapeutics in a research report on […]

Aeglea-biotherapeutics , Wells-fargo-company , Aeglea-biotherapeutics-company-profile , Aeglea-biotherapeutics-inc , Carlyle-group-inc , Sphera-funds-management , Free-report , Lifesci-capital , Get-free-report , Point-capital-management , Sigma-investments , Funds-management